Equity Long-Short Analyst

Pyari Menon

Pyari has over twenty years of experience in the industry, having worked on both the buy and sell-side including at Goldman Sachs, Credit-Suisse, Deutsche Bank, Intellectual Ventures, Tano Capital, and Franklin Templeton. His coverage has been in technology and midcaps across various geographies including Taiwan, ASEAN, India, the US, and Europe.

CVRx: Enhancing Cardiac Care Through Neuromodulation

CVRX: Great Technology that Now Has a Bright Future

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cvrx-inc" target="_blank" data-smartkarma-citation="entities:37498:1" rel="noopener">CVRx (CVRX US)</a> stock was up 28% (including after hours) post 3Q2024 results commentary</li>
<li>Reassignment to MS-DRG 276, Category I CPT Code Approval and BeAT-HF trial milestones suggest solid long term outlook.</li>
<li>CVRx’s unique Barostim technology and the rising demand for heart failure treatments driven by aging demographics and lifestyle-related cardiac issues make it a compelling acquisition target.</li>
</ul>



CVRx (CVRX US) stock was up 28% (including after hours) post 3Q2024 results commentary
Reassignment to MS-DRG 276, Category I CPT Code Approval and BeAT-HF trial milestones suggest solid long term outlook.
CVRx’s unique Barostim technology and the rising demand for heart failure treatments driven by aging demographics and lifestyle-related cardiac issues make it a compelling acquisition target.


CVRX: Saying It Again and Again, Barostim Is Great Technology with a Bright Future